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Background: In calculations of burden of disease using disability-adjusted life years, disability weights are needed
to quantify health losses relating to non-fatal outcomes, expressed as years lived with disability. In 2012 a new set
of global disability weights was published for the Global Burden of Disease 2010 (GBD 2010) study. That study
suggested that comparative assessments of different health outcomes are broadly similar across settings, but the
significance of this conclusion has been debated. The aim of the present study was to estimate disability weights
for Europe for a set of 255 health states, including 43 new health states, by replicating the GBD 2010 Disability
Weights Measurement study among representative population samples from four European countries.
Methods: For the assessment of disability weights for Europe we applied the GBD 2010 disability weights measurement
approach in web-based sample surveys in Hungary, Italy, Netherlands, and Sweden. The survey included paired
comparisons (PC) and population health equivalence questions (PHE) formulated as discrete choices. Probit
regression analysis was used to estimate cardinal values from PC responses. To locate results onto the 0-to-1 disability
weight scale, we assessed the feasibility of using the GBD 2010 scaling approach based on PHE questions, as well as an
alternative approach using non-parametric regression.
Results: In total, 30,660 respondents participated in the survey. Comparison of the probit regression results from the
PC responses for each country indicated high linear correlations between countries. The PHE data had high levels of
measurement error in these general population samples, which compromises the ability to infer ratio-scaled values
from discrete choice responses. Using the non-parametric regression approach as an alternative rescaling procedure,
the set of disability weights were bounded by distance vision mild impairment and anemia with the lowest weight
(0.004) and severe multiple sclerosis with the highest weight (0.677).
Conclusions: PC assessments of health outcomes in this study resulted in estimates that were highly correlated across
four European countries. Assessment of the feasibility of rescaling based on a discrete choice formulation of the PHE
question indicated that this approach may not be suitable for use in a web-based survey of the general population.
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Priority-setting for health care policies and research is
informed increasingly by burden of disease and injury
studies, because these studies provide knowledge on the
size of health problems and the potential benefit of pro-
posed interventions and policies directed against these
problems [1,2]. Burden of disease can be expressed in
disability-adjusted life years (DALYs), a summary meas-
ure of population health that captures health losses
associated with mortality and with different non-fatal
outcomes of diseases and injuries in a single figure [3-5].
The DALY methodology was developed in the 1990s for
the Global Burden of Disease (GBD) study [6-10] and has
since been used in many other disease burden studies (e.g.
[11-16]) as well as in cost-utility studies (e.g.[17-19]).
DALYs are calculated by adding years of life lost
(YLLs) and years lived with disability (YLDs). YLLs rep-
resent the life years lost due to premature death and are
calculated for any cause by multiplying the number of
deaths by a standardized expectation of remaining life
years at the age of death. YLDs represent the life years
lost due to disability, adjusted for the severity of the dis-
ability. YLDs are computed for a given health outcome
by multiplying the prevalence of that outcome by a
disability weight that has a value between 0 (equivalent
to full health) and 1 (equivalent to death).
For the 1996 revision of the GBD a large set of global
disability weights was derived in a group exercise in
which a panel of health experts assessed conditions
using a range of techniques, and the scale was deter-
mined largely by responses to two different variants of a
measurement method called the person trade-off [3,20].
This approach has been criticized, particularly regarding
aspects such as the health construct, measurement tech-
niques, and panel composition [21-23]. Because of a
need to improve the approach and a need for disability
weights that reflect the views of the global population, a
new approach to measuring disability weights was devel-
oped for the GBD 2010 study [24,25]. This study used a
conceptually less difficult measurement technique to
elicit health state valuations (paired comparisons instead
of the person trade-off). Health state descriptions focused
primarily on the impact of a condition on functional
health status. The study collected responses from 30,230
people in 167 countries. For five countries (Bangladesh,
Indonesia, Peru, Tanzania, and the United States of
America) household sample surveys were used, with sam-
ples designed to be representative of the population in a
particular geographical area (or in the case of the USA, na-
tionally representative). An important finding of the GBD
2010 disability weights study was that comparative assess-
ments of different disabling sequelae, as revealed in paired
comparisons, are similar in samples that vary with respect
to cultural, educational, environmental, and demographiccircumstances [25]. The GBD 2010 disability weights study
has been criticized regarding the estimated weights for cer-
tain conditions, such as vision loss, and for the interpret-
ation of evidence on the level of international agreement
in paired comparison responses [26,27].
For some purposes in which the need for standardization
and global comparison is not primary, it is useful to have
disability weights that reflect the particular views of a spe-
cific population under study, for example in a national bur-
den of disease study [28]. The present study was initiated
as part of a study on the burden of communicable diseases
in the European Union/European Economic Area (EEA)/
European Free Trade Association (EFTA) countries [29,30],
which motivates an interest in disability weights from
European population samples. The GBD 2010 disability
weights study did include respondents from European
countries; however, these respondents were not represen-
tative for these European countries, as they participated in
an open access web-based survey rather than in nationally
representative sample surveys. This raises a question as to
whether the current GBD 2010 disability weights are suit-
able for national burden of disease studies in European
countries.
The objectives of the present study were to:
1) Assess the feasibility of replicating the GBD 2010
disability weights measurement study in a set of four
nationally representative sample surveys in European
countries using web-based surveys.
2) Estimate disability weights for Europe for a set of
255 health states, including 43 new health states.
3) Evaluate consistency in comparative assessments of
disability across selected European countries.
Materials and methods
Study design
For the assessment of a set of disability weights for Europe
we replicated the online survey protocol used in the GBD
2010 disability weights measurement study [25].
Health states and description
In total 255 health states were evaluated. These health
states can be subdivided into four categories: original
GBD 2010 health states (n = 172) [25], new health states
(n = 43), modified GBD 2010 health states (n = 33), and
health states that were included for experimental purposes
but were not part of the European disability weights study
(n = 7).
Regarding the original GBD 2010 health states, we se-
lected all health states associated with infectious dis-
eases, injuries, and vision and hearing loss—of primary
interest for the new European study on communicable
disease—and supplemented these health states with a
further subset of GBD 2010 health states selected to
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state categories (e.g., cancer, cardiovascular and circula-
tory disease, diabetes, digestive and genitourinary disease,
chronic respiratory disease, musculoskeletal disorders,
neurological disorders, and other).
For the 43 new health states lay descriptions were con-
structed following the same general design principles
used in GBD 2010. The descriptions have a word limit
of 70 words or less and were constructed through an it-
erative process. The brief lay descriptions are intended
to highlight the major functional consequences and
symptoms associated with the health state using simple,
non-clinical vocabulary. Disease experts and health pro-
fessionals were consulted to ensure that the descriptions
were appropriate and reflective of the common manifes-
tations of the disabling sequela in question.
For the 33 modified health states the description of the
health states of original GBD health states were amended
because they were found to be lacking in consistency or in
content [25,26]. For instance, in the case of spinal cord in-
jury, incontinence was added to the description. Both the
original and modified health state descriptions were
evaluated in this study in order to facilitate direct com-
parison. The health state descriptions that were evalu-
ated in this study are included in Additional file 1.
Health state valuation
To elicit health state valuations for the 255 health states,
two valuation techniques were used: paired comparison
(PC) and population health equivalence (PHE). All of the
255 health states were evaluated with the PC technique,
and a subset of 28 states were evaluated with PHE ques-
tions. Paired (sometimes called “pairwise”) comparison is
an ordinal measurement method. With this method, per-
sons in two alternative health states are presented, and
respondents have to decide whom they regard as being
healthier. PHE questions ask for a retrospective assess-
ment that compares two hypothetical health programs.
The first health program prevented 1,000 people from get-
ting an illness that causes rapid death; the second health
program prevented 1,500, 2,000, 3,000, 5,000, or 10,000
(dependent on the bid that was selected randomly for each
question) people from getting an illness that is not fatal
but causes the lifelong health problems of one of the se-
lected health states. The respondents are asked to choose
which health program they think produced the greater
overall population health benefit.
The 28 health states that were evaluated here were a
subset of the 30 health states evaluated with the PHE in
the GBD 2010 disability weights study.
Panel participants
The panel consisted of members of the general public
aged 18 to 65 years from four European countries, namelyHungary, Italy, the Netherlands, and Sweden. We selected
these four countries because they are believed to be repre-
sentative of four regions of Europe (Eastern, Southern,
Central, and Northern Europe) with regards to age, sex,
and educational level. We used existing large internet
panels in the selected European countries. By selecting
panel members with certain characteristics (in our case:
age, sex, and educational level) from the existing large
panels, the panel of participants for this study could be
composed in such a way that the respondents were repre-
sentative of the population aged 18 to 65 in the selected
countries. The procedure to invite panelists to fill in the
questionnaire differed between the Netherlands and the
other three countries. In the Netherlands panelists were
invited via individual emails. In the three other countries a
link to the questionnaire was placed on a website. Subse-
quently, the relevant respondents were selected based on
their characteristics as assessed in the questionnaire. Be-
cause of this, the specific number of panelists that were
invited to fill in the questionnaire in Hungary, Italy, and
Sweden is not known, and the response rate could not be
calculated for these countries.
Data collection
The GBD 2010 disability weights study consisted of two
main components: a) a face-to-face or telephone survey
based on a subset of the sequelae (household survey) and
b) a web-based survey based on the full set of sequelae. In
the current study we used the GBD 2010 web-based sur-
vey instrument.
Three versions of the web-based survey were developed.
The number and framing of the PC questions differed per
version. Each version included questions regarding the
demographics of the respondent (age, sex, educational and
income level, and disease experience) and three PHE and
PC questions. The first version of the questionnaire in-
cluded 15 PC questions with a chronic framing, the sec-
ond version included 15 PC questions with a temporary
framing, and the third version included five PC questions
with a chronic framing to accommodate PHE questions.
Chronic framing means that the participants are asked to
consider the situation that the described health state will
last for the rest of a person’s life. Temporary framing
means that the participant is asked to consider that the
health state will last for one week.
The survey and description of health states were trans-
lated from English into Dutch, Hungarian, Italian, and
Swedish using translation software and subsequently
translated back into English. The translations were veri-
fied independently by bilingual native speakers.
In the period 23 September to 11 November 2013 the
disability weight survey was administered via the internet.
The survey versions and health states were randomly
assigned to the respondents following a randomization
Table 1 Characteristics of the 30,600 participants
Sex
Male 48.0%
Age (years)
18-34 31.2%
35-49 35.1%
50-65 33.7%
Educational level
Low 29.8%
Medium 45.7%
High 24.6%
Income level
Low 39.5%
Medium 45.4%
High 15.1%
Country
Hungary 19.8%
Italy 26.3%
Netherlands 26.2%
Sweden 27.8%
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vey version, based on the lowest percentage of respon-
dents at that moment for each version. After the version
was allocated, the algorithm selected the health states
based on the minimum number of allocations that the
health state had at that moment, i.e., the probability of
selection was inversely proportional to number of alloca-
tions that health state at that moment.
Data analysis
Analyses were performed with R (version 3.0.2) [31] and
SPSS (version 21). The PC data were analyzed through
probit regression, following the approach used in GBD
2010 [25]. Coefficients from the probit regression were
compared across the four European countries in order to
assess variation in the comparative assessments of different
disabilities, as expressed in paired comparisons. To exam-
ine the feasibility of using the PHE rescaling method from
the GBD 2010, we evaluated the PHE data in terms of the
probabilities of choosing the alternative program over the
first program by health state and by bid, as well as by edu-
cational level. This analysis thus focused on “sensitivity to
scope” in the PHE [32], i.e., the degree to which bid prob-
abilities are dependent on the number of people benefiting
from the program, as the conceptual model for analyzing
PHE data presumes, as well as responsiveness to variation
in the severity of the different outcomes under consider-
ation, i.e., the degree to which bid probabilities are sensitive
to the nature of the health outcomes affected by the two
programs in each comparison. As an alternative rescaling
procedure, we ran a non-parametric regression model
(loess) of the probit regression coefficients against the
logit-transformed disability weights from GBD 2010. Based
on this loess fit, we then predicted logit transformed dis-
ability weights for each of the probit coefficients, including
the ones that were not matched to a GBD 2010 health
state. Finally, we applied an inverse logit transformation at
the draw level to these predicted disability weights. Uncer-
tainty intervals around the mean disability weights were
estimated through a Monte Carlo simulation approach.
First, 200 samples of the paired comparison coefficients
were generated based on their probit estimated mean and
standard deviation. These samples were then used to pro-
duce 200 loess fits, as described above. Based on each loess
fit, 200 samples were generated for each of the disability
weights, yielding a total of 40,000 samples per disability
weight. Uncertainty intervals around the mean disability
weights were derived as the 2.5th and 97.5th percentile of
the corresponding distribution of sampled weights.
Results
Respondents
A total of 30,660 respondents filled in the questionnaire.
Approximately half of the respondents were male. Theaverage age was 42.3 (SD 13.1). 76% of the respondents
had a low or medium educational level and the majority
(84.9%) had a low to medium income level. Table 1 shows
the characteristics of the respondents. The response rate
in the Netherlands was 63.1%. The response rates of the
other countries could not be calculated.
Paired comparison
Figure 1 shows a heat map of the paired comparison
response probabilities for the 255 × 255 possible paired
comparisons. Each cell in the heat map indicates the
response probability for one pair of states. The colors of
the heat map correspond to the probability that the first
health state in a pair comparison is chosen as the health-
ier outcome. Figure 1 shows a relatively smooth transition
in colors from high to low probabilities between the upper
left and lower right corner, indicating a small amount of
measurement error and high internal consistency.
Of the respondents, 6.9% were given the same pair in
the first and 15th paired comparison question, and of
these 51% were presented in the same order and 49% in
reversed order. This deliberate repetition allows assess-
ment of test-retest reliability of PC responses. Overall,
the probability of choosing the same health state was
slightly higher if the two health states were presented in
the same order (probability of choosing the same health
state: 0.75) compared to reversed order (probability of
choosing the same health state: 0.73). This is above the
probability of chance agreement (0.50). The probabilities
Figure 1 Response probabilities for paired comparisons. Red corresponds to probabilities that are 0.25 or lower. Blue corresponds to probabilities
that are 0.75 or higher. Green, yellow, and orange correspond to probabilities between 0.25 and 0.75. A smooth transition in colors from high to low
probabilities between the upper left and lower right corners indicates a small amount of measurement error and high internal consistency, whereas a
completely random assortment of colors would indicate a high amount of measurement error and low internal consistency. It should be noted that not
every possible 255 × 255 pair was evaluated with the pairwise comparison. This is indicated by the white spaces in the figure.
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the Netherlands (n = 553), and Sweden (n = 573) chose
the same health state in the retest were 0.78, 0.72, 0.73,
and 0.75, respectively.
Comparison of the regression results on the paired
comparison responses for each country with those run
on the pooled data showed high linear correlations in all
four cases (Pearson’s correlation coefficients between
0.855 and 0.978; p < 0.001; see Table 2).
Population health equivalence
With the PHE a choice has to be made between two
hypothetical health programs. We found that the prob-
ability of choosing the second health program option
was higher as the bid increased (i.e., when the number
of beneficiaries was greater), as expected. However, the
span of probabilities between the lowest bid value (withTable 2 Pearson’s correlation coefficients for country-
specific and pooled probit regression analyses of paired
comparison responses
Hungary Italy Sweden Pooled
Netherlands 0.867* 0.855* 0.894* 0.941*
Hungary - 0.944* 0.929* 0.966*
Italy - 0.935* 0.967*
Sweden - 0.978*
*correlation is significant at the 0.01 level.1,500 beneficiaries) and the highest bid value (with
10,000 beneficiaries) was generally lower than expected
and varied by educational level on the PHE responses.
On average, the differences between the probabilities of
choosing the second health program at the highest versus
the lowest bid values were 0.12, 0.16, and 0.19 for the
lower, middle, and higher educational level, respectively.
The responsiveness to variation in the severity of the
different outcomes under consideration was also lower
than expected. While the 28 health states could be
ranked according to the probabilities of choosing the
second program (which prevented a specified number of
cases of each outcome), there was relatively little vari-
ation across the range of health outcomes with quite
distinct profiles of severity.
Figure 2 shows the probabilities of choosing the sec-
ond program at each bid value for each of the 28 health
states that were evaluated with the PHE. For compari-
son, a similar graph of the PHE data from the GBD 2010
disability weights measurement study is presented. The
graphs show that the GBD 2010 PHE data had better
discrimination by bid (higher sensitivity to scope), illus-
trated by longer lines between the bids within one health
state, as well as a better discrimination by health state
(better responsiveness to variation in the severity of the
different outcomes), illustrated by a steeper gradient
across health states, moving from left to right. These
results suggest that the PHE responses in the present
Figure 2 Probability of choosing the second program at each bid value for each of the 28 health states that were evaluated with the
population health equivalence questions, in the present study (top panel) compared to results in the GBD 2010 study (bottom panel).
Each line represents one health state and each dot represents a bid within one health state.
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consequently, the feasibility of using discrete choice
formulation in general population web-based sample
surveys may be questioned.
Disability weights
Given the evident lack of feasibility of the discrete
choice PHE in this sample, a non-parametric regression
approach was used as an alternative rescaling procedure
to locate results onto the 0-to-1 disability weight scale.
The R-squared from that regression was 0.801, based
on 172 health states that were in both studies. The
resulting disability weights and 95% uncertainty interval
(UI) are shown in Table 3 (original GBD 2010 health
states, new health states, and modified GBD 2010
health states). Distance vision mild impairment and
mild anemia shared the lowest disability weight (0.004)
and severe multiple sclerosis had the highest disability
weight (0.677).
The results show that the disability weights are ranked
logically; lowest disability weights were attributed to
mild health states, such as mild hearing impairment
(disability weight 0.011) and mild acute infectious
disease (disability weight 0.007), and highest disability
weights were attributed to severe health states, such
as the terminal phase of cancer or chronic kidney dis-
ease without medication (disability weight 0.588) anduntreated spinal cord lesion below neck level (disability
weight 0.648). This is illustrated by increasing disability
weights by level of severity within specific types of
diseases. For example, mild diarrhea (disability weight
0.073) is rated lower than moderate diarrhea (disability
weight 0.149) and severe diarrhea (disability weight
0.239).
Comparison to GBD disability weights
For 141 (82.0%) of the 172 health states that were
included in the European and GBD studies, the point
estimate of the European disability weight fell within the
95% UI of the GBD 2010 disability weights. For 17
(10.1%) health states the European disability weights
were higher than the upper bound, and for 11 (6.5%)
health states the European disability weights were lower
than the lower bound of the 95% UI from the GBD 2010
study.
In absolute terms, differences between GBD and
European disability weights ranged from −0.165 (HIV,
cases, symptomatic, pre-AIDS; GBD 2010 disability
weight = 0.186, European disability weight = 0.351) to
0.185 (fracture of pelvis, short term; GBD 2010 disability
weight = 0.390, European disability weight = 0.205). The
relative difference ranged from 0% to 61%, with the high-
est relative differences generally appearing in cases of low
disability weights (asthma controlled GBD 2010 disability
Table 3 Estimated disability weights with uncertainty intervals (UI)
Disability weight (+ UI)
Category1 Mean 2.5% 97.5%
Infectious diseases
Original Infectious disease, acute episode, mild 0.007 0.005 0.01
Original Infectious disease, acute episode, moderate 0.051 0.039 0.06
Original Infectious disease, acute episode, severe 0.125 0.104 0.152
Original Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia) 0.217 0.179 0.251
Original Diarrhea, mild 0.073 0.061 0.092
Original Diarrhea, moderate 0.149 0.12 0.182
Original Diarrhea, severe 0.239 0.202 0.285
Original Epididymo-orchitis 0.176 0.143 0.208
Original HIV cases, symptomatic, pre-AIDS 0.351 0.299 0.394
Original HIV/AIDS cases, receiving ARV treatment 0.108 0.089 0.132
Original AIDS cases, not receiving ARV treatment 0.574 0.518 0.635
Original Ear pain 0.015 0.011 0.019
Original Tuberculosis, not HIV infected 0.308 0.264 0.353
Original Tuberculosis, HIV infected 0.383 0.345 0.435
Original Tuberculosis of vertebrae 0.287 0.245 0.332
New Subacute sclerosing panencephalitis – phase 1 0.088 0.07 0.108
New Thrombocytopenic purpura 0.167 0.134 0.201
New Lymphogranuloma Venereum - local infection 0.070 0.057 0.087
New Subacute sclerosing panencephalitis – phase 2 0.276 0.235 0.323
New Subacute sclerosing panencephalitis – phase 3 0.543 0.481 0.606
Cancer
Original Cancer, diagnosis and primary therapy 0.265 0.222 0.303
Original Cancer, metastatic 0.358 0.317 0.417
Original Stoma 0.125 0.104 0.155
Original Terminal phase, with medication (for cancers, end-stage kidney/liver disease) 0.515 0.459 0.572
Original Terminal phase, without medication (for cancers, end-stage kidney/liver disease) 0.588 0.524 0.65
Cardiovascular and circulatory disease
Original Acute myocardial infarction, days 3-28 0.098 0.08 0.121
Original Angina pectoris, moderate 0.103 0.089 0.128
Original Cardiac conduction disorders and cardiac dysrhythmias 0.295 0.258 0.343
Original Heart failure, mild 0.052 0.041 0.063
Original Heart failure, moderate 0.070 0.057 0.085
Original Heart failure, severe 0.173 0.14 0.205
Original Stroke, long-term consequences, moderate 0.075 0.059 0.093
Original Stroke, long-term consequences, severe plus cognition problems 0.580 0.519 0.639
Diabetes, digestive, and genitourinary disease
Original Diabetic neuropathy 0.165 0.134 0.199
Original Chronic kidney disease (stage IV) 0.108 0.09 0.132
Original End-stage renal disease, on dialysis 0.487 0.432 0.544
Original End-stage renal disease, with kidney transplant 0.030 0.023 0.037
Original Decompensated cirrhosis of the liver 0.163 0.136 0.194
Original Crohn's disease or ulcerative colitis 0.221 0.184 0.26
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Table 3 Estimated disability weights with uncertainty intervals (UI) (Continued)
Original Infertility, primary 0.008 0.005 0.01
Original Infertility, secondary 0.007 0.005 0.01
New Heart burn & reflux “GERD” 0.038 0.029 0.046
New Constipation 0.075 0.061 0.092
New Vaginal discharge 0.018 0.013 0.022
New Dyspareunia 0.022 0.017 0.027
New Irritable bowel syndrome 0.062 0.05 0.077
New Stress incontinence 0.032 0.024 0.038
Chronic respiratory diseases
Original Asthma, controlled 0.020 0.015 0.024
Original Asthma, partially controlled 0.045 0.035 0.055
Original COPD and other chronic respiratory problems, mild 0.025 0.019 0.031
Original COPD and other chronic respiratory problems, moderate 0.284 0.242 0.329
Original COPD and other chronic respiratory problems, severe 0.418 0.367 0.468
Mental, behavioural, and substance abuse disorder
New Harmful alcohol use 0.106 0.087 0.132
New Alcohol use disorder, very mild 0.154 0.123 0.187
Original Alcohol use disorder, mild 0.209 0.175 0.247
Original Alcohol use disorder, moderate 0.357 0.309 0.41
Original Alcohol use disorder, severe 0.500 0.457 0.567
New Cannabis dependence, mild 0.043 0.033 0.052
Original Cannabis dependence 0.191 0.147 0.235
New Amphetamine dependence, mild 0.088 0.072 0.11
Original Amphetamine dependence 0.474 0.417 0.531
New Cocaine dependence, mild 0.131 0.107 0.163
Original Cocaine dependence 0.493 0.444 0.549
New Opioid dependence, mild 0.365 0.314 0.417
Original Heroin and other opioid dependence 0.624 0.553 0.707
Original Anxiety disorders, mild 0.045 0.035 0.054
Original Anxiety disorders, moderate 0.119 0.098 0.15
Original Anxiety disorders, severe 0.422 0.372 0.475
Modified Major depressive disorder, mild episode 0.129 0.102 0.154
Original Major depressive disorder, moderate episode 0.294 0.248 0.341
Original Major depressive disorder, severe episode 0.571 0.509 0.635
Modified Intellectual disability, borderline 0.014 0.01 0.017
Modified Intellectual disability, mild 0.053 0.041 0.065
Modified Intellectual disability, moderate 0.123 0.097 0.152
Modified Intellectual disability, severe 0.141 0.112 0.174
Modified Intellectual disability, profound 0.213 0.177 0.255
New Borderline personality disorder 0.193 0.16 0.228
New Somatoform disorder 0.144 0.116 0.174
Hearing and vision loss
Modified Hearing loss, mild 0.011 0.007 0.014
Modified Hearing loss, moderate 0.037 0.028 0.045
Modified Hearing loss, severe 0.152 0.125 0.187
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Table 3 Estimated disability weights with uncertainty intervals (UI) (Continued)
Modified Hearing loss, profound 0.235 0.197 0.274
Modified Hearing loss, mild, with ringing 0.027 0.021 0.034
Modified Hearing loss, moderate, with ringing 0.070 0.056 0.087
Modified Hearing loss, severe, with ringing 0.274 0.231 0.318
Modified Hearing loss, profound, with ringing 0.242 0.204 0.288
Modified Hearing loss, complete, with ringing 0.313 0.268 0.361
Original Unilateral hearing loss 0.008 0.005 0.012
Original Near vision impairment 0.012 0.008 0.015
Original Distance vision, mild impairment 0.004 0.002 0.005
Original Distance vision, moderate impairment 0.034 0.027 0.042
Original Distance vision, severe impairment 0.158 0.13 0.193
Modified Distance vision blindness 0.173 0.145 0.213
Musculoskeletal disorders
Original Back pain, acute, with leg pain 0.275 0.237 0.324
Original Back pain, acute, without leg pain 0.298 0.254 0.343
Original Back pain, chronic, with leg pain 0.395 0.345 0.45
Original Back pain, chronic, without leg pain 0.365 0.322 0.413
New Low back pain, mild 0.024 0.018 0.03
New Low back pain, moderate 0.060 0.05 0.074
Original Neck pain, acute, mild 0.062 0.05 0.075
Original Neck pain, acute, severe 0.224 0.19 0.268
Original Neck pain, chronic, mild 0.111 0.089 0.136
New Neck pain, moderate 0.056 0.044 0.067
Original Neck pain, chronic, severe 0.311 0.263 0.359
Original Musculoskeletal problems, lower limbs, mild 0.027 0.021 0.032
Original Musculoskeletal problems, lower limbs, moderate 0.094 0.08 0.12
Original Musculoskeletal problems, lower limbs, severe 0.134 0.11 0.165
Original Musculoskeletal problems, upper limbs, mild 0.041 0.032 0.05
Original Musculoskeletal problems, upper limbs, moderate 0.138 0.114 0.167
Original Musculoskeletal problems, generalized, moderate 0.344 0.3 0.391
Original Musculoskeletal problems, generalized, severe 0.518 0.457 0.576
New Osteomyelitis 0.053 0.041 0.065
New Shoulder lesions 0.016 0.012 0.02
Injuries
Modified Amputation of finger(s), excluding thumb 0.007 0.005 0.009
Original Amputation of thumb (long term) 0.015 0.011 0.018
New Amputation of one upper limb (long term, without treatment) 0.105 0.085 0.128
Modified Amputation of one upper limb (with treatment) 0.048 0.037 0.057
Modified Amputation of both upper limbs (long term, with treatment) 0.121 0.097 0.153
Modified Amputation of both upper limbs (long term, without treatment) 0.392 0.344 0.451
Modified Amputation of one lower limb (long term, with treatment) 0.041 0.031 0.049
Original Amputation of one lower limb (long term, without treatment) 0.188 0.153 0.225
Modified Amputation of both lower limbs (long term, with treatment) 0.088 0.071 0.107
Modified Amputation of both lower limbs (long term, without treatment) 0.427 0.381 0.484
Original Amputation of toe 0.007 0.005 0.009
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Table 3 Estimated disability weights with uncertainty intervals (UI) (Continued)
Original Burns, <20% total burned surface area without lower airway burns (short term, with or without treatment) 0.154 0.125 0.189
Original Burns, <20% total burned surface area or <10% total burned surface area if head/neck or hands/wrist involved
(long term, with or without treatment)
0.019 0.014 0.024
Original Burns, ≥20% total burned surface area (short term, with or without treatment) 0.262 0.218 0.303
Original Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist involved
(long term, with treatment)
0.161 0.131 0.195
Original Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist involved
(long term, without treatment)
0.424 0.372 0.478
Original Crush injury (short or long term, with or without treatment) 0.138 0.112 0.169
Original Dislocation of hip (long term, with or without treatment) 0.018 0.014 0.023
Original Dislocation of knee (long term, with or without treatment) 0.112 0.094 0.141
Original Dislocation of shoulder (long term, with or without treatment) 0.041 0.033 0.051
Original Other injuries of muscle and tendon (includes sprains, strains and dislocations other than shoulder, knee, hip) 0.009 0.007 0.012
Original Drowning and nonfatal submersion (short or long term, with or without treatment) 0.240 0.197 0.286
Original Fracture of clavicle, scapula or humerus (short or long term, with or without treatment) 0.038 0.029 0.045
Modified Fracture of face bone (short or long term with or without treatment) 0.038 0.031 0.044
Original Fracture of foot bones (short term, with or without treatment) 0.027 0.021 0.033
Original Fracture of foot bones (long term, without treatment) 0.026 0.019 0.032
Original Fracture of hand (short term, with or without treatment) 0.010 0.007 0.013
Original Fracture of hand (long term, without treatment) 0.020 0.015 0.026
Original Fracture of neck of femur (short term, with or without treatment) 0.228 0.193 0.275
Original Fracture of neck of femur (long term, with treatment) 0.057 0.045 0.068
Original Fracture of neck of femur (long term, without treatment) 0.440 0.391 0.493
Original Fracture of patella, tibia or fibula or ankle (short term, with or without treatment) 0.044 0.034 0.053
Original Fracture of patella, tibia or fibula or ankle (long term, with or without treatment) 0.051 0.04 0.062
Original Fracture of pelvis (short term) 0.205 0.171 0.243
Original Fracture of pelvis (long term) 0.158 0.127 0.194
Original Fracture of radius or ulna (short term, with or without treatment) 0.030 0.024 0.037
Original Fracture of radius or ulna (long term, without treatment) 0.052 0.042 0.063
Original Fracture of skull (short or long term, with or without treatment) 0.083 0.066 0.103
Original Fracture of sternum and/or fracture of one or two ribs (short term, with or without treatment) 0.185 0.161 0.21
Original Fracture of vertebral column (short or long term, with or without treatment) 0.101 0.084 0.124
Original Fracture, other than femoral neck (short term, with or without treatment) 0.080 0.064 0.097
Original Fracture, other than femoral neck (long term, without treatment) 0.042 0.032 0.051
Original Fractures, treated (long term) 0.005 0.004 0.008
Original Injured nerves (short term) 0.126 0.104 0.156
Original Injured nerves (long term) 0.074 0.059 0.088
Original Injury to eyes (short term) 0.060 0.048 0.072
New Concussion 0.104 0.085 0.126
Original Traumatic brain injury, long-term consequences, minor (with or without treatment) 0.089 0.072 0.109
Original Traumatic brain injury, long-term consequences, moderate (with or without treatment) 0.214 0.18 0.252
Original Severe traumatic brain injury, short term (with or without treatment) 0.192 0.151 0.228
Original Traumatic brain injury, long-term consequences, severe (with or without treatment) 0.604 0.539 0.674
Original Open wound (short term, with or without treatment) 0.007 0.005 0.01
Original Poisoning (short term with or without treatment) 0.170 0.139 0.202
Original Severe chest injury (short term, with or without treatment) 0.377 0.333 0.434
Haagsma et al. Population Health Metrics  (2015) 13:10 Page 10 of 15
Table 3 Estimated disability weights with uncertainty intervals (UI) (Continued)
Original Severe chest injury (long term, with or without treatment) 0.047 0.036 0.056
Modified Spinal cord lesion below neck level (treated) 0.298 0.256 0.349
Modified Spinal cord lesion below neck level (untreated) 0.619 0.553 0.696
Modified Spinal cord lesion at neck level (treated) 0.520 0.465 0.581
Modified Spinal cord lesion at neck level (untreated) 0.648 0.578 0.728
Neurological disorders
Original Dementia, mild 0.059 0.048 0.073
Original Dementia, moderate 0.434 0.38 0.481
New Encephalopathy - moderate 0.410 0.358 0.47
New Encephalopathy - severe 0.447 0.391 0.501
New Epilepsy, seizures > = once a month 0.488 0.432 0.546
New Epilepsy, seizures 1–11 per year 0.255 0.215 0.294
Original Epilepsy, severe 0.562 0.505 0.631
Original Epilepsy, treated, with recent seizures 0.335 0.294 0.388
Original Multiple sclerosis, mild 0.160 0.128 0.195
Original Multiple sclerosis, moderate 0.469 0.417 0.531
Original Multiple sclerosis, severe 0.677 0.594 0.757
Original Parkinson's disease, mild 0.016 0.012 0.022
Original Parkinson's disease, moderate 0.239 0.205 0.286
Original Parkinson's disease, severe 0.530 0.477 0.59
New Trigeminal neuralgia 0.068 0.056 0.084
New Vertigo and balance disorder (Menière, labyrinthitis) 0.097 0.079 0.119
Other
Original Abdominopelvic problem, mild 0.018 0.013 0.022
Original Abdominopelvic problem, moderate 0.123 0.1 0.15
Original Abdominopelvic problem, severe 0.310 0.262 0.355
New Allergic rhinitis (hay fever) 0.006 0.004 0.009
New Anal fissure/abscess/fistula 0.082 0.066 0.1
Original Anemia, mild 0.004 0.003 0.006
Original Anemia, moderate 0.045 0.035 0.054
Original Anemia, severe 0.118 0.098 0.145
New Carpal tunnel syndrome 0.039 0.031 0.047
Original Conjunctivitis without corneal scar 0.015 0.011 0.019
Modifed Generic uncomplicated disease: anxiety about diagnosis 0.021 0.015 0.026
Original Generic uncomplicated disease: worry and daily medication 0.070 0.057 0.088
New Haemorrhoids 0.109 0.085 0.133
New Hyperthyroidism 0.144 0.115 0.176
New Hypothyroidism 0.022 0.017 0.028
New Insomnia 0.023 0.017 0.028
New Intensive care unit admission 0.655 0.579 0.727
New Invasive device/drain 0.163 0.131 0.198
Original Motor impairment, mild 0.011 0.008 0.014
Original Motor impairment, moderate 0.053 0.042 0.064
Original Motor impairment, severe 0.421 0.377 0.477
Modified Motor plus cognitive impairments, mild 0.044 0.035 0.053
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Table 3 Estimated disability weights with uncertainty intervals (UI) (Continued)
Modified Motor plus cognitive impairments, moderate 0.185 0.154 0.223
Modified Motor plus cognitive impairments, severe 0.494 0.438 0.557
New Sleep apnoea 0.036 0.027 0.044
New Varicose veins 0.020 0.016 0.025
1Original = original GBD 2010 health states [25]; New = new health states; Modified =modified GBD 2010 health states.
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tures treated, long term GBD 2010 disability weight =
0.003, European disability weight = 0.005).
Discussion
This study aimed to assess disability weights for 255
health states. The resulting disability weights were
ranked logically; the lowest disability weights were at-
tributed to mild health states and the highest disability
weights to severe health states. Furthermore, the results
pointed to a high level of overall agreement in paired
comparison responses across four countries, as indicated
by high linear correlations in country-specific results
from probit regression analyses.
Strengths of the current study
Thus far, the largest European disability weights study,
published in 2003, included 232 respondents [33]. Apart
from a lower number of health states, different valuation
techniques and sample size, the study of Schwarzinger
et al. utilized a different panel composition, namely
health professionals rather than a population panel [33].
Since burden of disease studies are used primarily as a
tool for decision-making on resource allocation at a
population level, it has been recommended to incorpor-
ate the views of the general public to inform decision-
making in a democratic society [25,28]. However, the
majority of previously performed disability weight stud-
ies asked health professionals to value health states.
Studies that included both medical experts and mem-
bers of the general public showed significant differences
between disability weights derived from these two
groups [34-36].
Web-based survey
A limitation of this study is that we used a web-based
survey to collect the data. Internet users tend to be more
highly educated and younger than the general EU popu-
lation [37]. We have tried to mitigate these limitations
by using existing large internet panels in the selected
European countries. By selecting panel members with
certain characteristics (in our case, age, sex, and educa-
tional level) from the existing large panel, the panel of
participants for this study could be composed in such a
way that it was representative of the population aged 18
to 65 years in the selected countries. Our panel did notinclude participants older than 65 years. For the age
groups over age 65 it was too difficult to find enough
participants. The GBD 2010 disability weights study did
include respondents aged 65 and older (approximately
5% of the total sample).
Population health equivalence
Based on responses to population health equivalence
questions, as expected, the probability of choosing the
second health program option was higher with increas-
ing bid (i.e., a higher number people that are prevented
from getting a certain illness). However, the differences
between the choice probabilities with the highest (10,000
people prevented from getting a certain illness) and low-
est bids (1,500 people prevented from getting that
illness) were small. The relatively small difference is con-
sistent with large numbers of respondents answering
randomly, which will drive all aggregate-level response
probabilities toward 50% and thus dilute differences
across types of outcomes (either defined by different
numbers of beneficiaries or different severity of the
health state under consideration). The spans in response
probabilities between the low and high bids were smal-
lest among those with lower education. In the GBD
study, the PHE was included in the web-based survey as
well [25]. However, the educational level of the respon-
dents of the GBD study was much higher (93% with a
higher education) compared to our study (25% with a
higher education), and respondents to the GBD survey
were a self-selected group who were evidently interested
enough in the content of the survey to participate volun-
tarily. This may have resulted in greater attention to the
question and care in weighing the responses, both of
which are likely to have improved the signal-to-noise
ratio in the responses. We conclude from the results in
the present study that the discrete choice formulation of
the PHE may not be suitable for use in a general popula-
tion survey administered by the internet.
Disability weights
The ranking of certain conditions seems counterintui-
tive. For instance, the disability weight for profound
intellectual disability is lower than the disability weight
for back pain. A possible explanation for this may be
that brief lay descriptions were used to describe the
major functional consequences and symptoms associated
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ing the cause of the health state, was removed from the
description. The latter was a deliberate choice, because
the disease label may elicit bias for stigmatizing condi-
tions [25]. However, previous studies showed that
including certain disease information in health state
descriptions yields different values [38]. A second ex-
planation may be the framing of the paired comparison.
In the pairwise comparison respondents are asked to
judge the level of health of the health states, and this
may lead to bias if respondents consider some health
states as not being associated with “being ill” [26].
For future health state valuation studies that use a
similar design and a similar panel composition it is
important to consider different techniques to anchor
estimates from paired comparisons onto the disability
weight scale, such as the time trade-off or the standard
gamble. However, each of these existing techniques to
measure health state preferences suffers from limitations
that hamper their application in a study design where a
web-based survey is used to collect health state valua-
tions from a panel that consists of members of the
general public. Alternatively, the disability weights may
be recalibrated post-hoc by health professionals. Health
professionals are argued to have the ability to make
careful comparative judgments. However, an argument
against the use of a panel composed of health profes-
sionals is that the disability weights will not entirely
reflect the views of the global population, as has been
recommended.
Agreement between European disability weights and
GBD 2010 disability weights
Given the lack of feasibility of the discrete choice PHE in
this sample, an alternative rescaling procedure was applied
based on non-parametric regression. It is important to
note that as a result, this study does not include new
information on tradeoffs between nonfatal and fatal out-
comes, which are central to the rescaling of results to a
unique 0-to-1 disability weights scale. We therefore
emphasize that comparison of disability weights between
this study and GBD 2010 should be understood as reflect-
ing variation in comparative evaluations of different
functional outcomes (as manifest in responses to paired
comparison questions) rather than a complete assessment
of differences in the valuation of nonfatal versus fatal
health outcomes.
Cultural differences
Similar to the GBD 2010 disability weights measurement
study, our study aspired to quantify health loss as op-
posed to welfare loss [25]. Previous studies have shown
that there are clear cultural differences in the ways
people perceive health problems and how such problemsaffect their lives [39-43]. This was endorsed by Üstün
et al., who found significant differences in ranking of
health states between 14 countries [36]. Furthermore,
the findings from Jelsma et al. suggest that the effect of
cultural differences on health state valuations may be
stronger among lay people compared to health profes-
sionals [35]. However, in the largest disability weights
study thus far, Salomon et al. found that comparative
paired comparisons of different functional outcomes
produced similar results in samples that varied with re-
spect to cultural, educational, environmental, and demo-
graphic circumstances [25]. The current study also
found a high degree of consistency between countries,
though it should be noted that all of the countries in our
study were high-income European settings, so we cau-
tion against over-generalization of the significance of the
findings. Apart from cultural differences, other differ-
ences between high- and low-income settings may also
influence how people weigh different health outcomes.
For example, we might hypothesize that diseases and
injuries rated as less severe by experts in a high-income
country could be rated as more burdensome by people
in low-income settings. Further research is needed to
gain greater insight into the effects of cultural differ-
ences on disability weights, particularly in low-income
settings.
Conclusions
Limitations notwithstanding, this study provided an
opportunity to expand the evidence base on disability
weights derived from the GBD disability weights meas-
urement study, since PC assessments of health outcomes
in this study resulted in estimates that were highly corre-
lated across four European countries. Furthermore, the
European disability weights study provided the oppor-
tunity to expand the set of health outcomes that will be
covered in the burden of communicable disease study in
the European Union/EEA/EFTA countries and the next
revision of the GBD.
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